Asthma pharmacotherapy: an update on leukotriene treatments

References

• Global Initiative of Asthma. Global Strategy for Asthma Management and Prevention 2019 [ cited 2019 Jun 1]. Available from: https://ginasthma.org/
   Google Scholar
• Nunes C, Pereira AM, Morais-Almeida M. Asthma costs and social impact. Asthma Res Pract. 2017;3:1.
   PubMedGoogle Scholar
• Lang DM. Severe asthma: epidemiology, burden of illness, and heterogeneity. Allergy Asthma Proc. 2015;36:192–199.
   Web of Science ®Google Scholar
• Park SY, Kim JH, Kim HJ, et al. High prevalence of asthma in elderly women: findings from a Korean national health database and adult asthma cohort. Allergy Asthma Immunol Res. 2018;10:387–396.
   PubMed Web of Science ®Google Scholar
• Kim SH, Moon JY, Lee JH, et al. Perceptions of severe asthma and asthma-COPD overlap syndrome among specialists: a questionnaire survey. Allergy Asthma Immunol Res. 2018;10:225–235.
   PubMed Web of Science ®Google Scholar
• Kanaoka Y, Boyce JA. Cysteinyl leukotrienes and their receptors; emerging concepts. Allergy Asthma Immunol Res. 2014;6:288–295.
   PubMed Web of Science ®Google Scholar
• Peters-Golden M, Henderson WR Jr. The role of leukotrienes in allergic rhinitis. Ann Allergy Asthma Immunol. 2005;94: 609–618. quiz 18-20, 69.
   PubMed Web of Science ®Google Scholar
• Higgins AJ, Lees P. The acute inflammatory process, arachidonic acid metabolism and the mode of action of anti-inflammatory drugs. Equine Vet J. 1984;16:163–175.
   PubMed Web of Science ®Google Scholar
• Yokomizo T, Nakamura M, Shimizu T. Leukotriene receptors as potential therapeutic targets. J Clin Invest. 2018;128:2691–2701.
   PubMed Web of Science ®Google Scholar
• Thompson MD, Capra V, Clunes MT, et al. Cysteinyl leukotrienes pathway genes, atopic asthma and drug response: from population isolates to large genome-wide association studies. Front Pharmacol. 2016;7:299.
   Web of Science ®Google Scholar
• Morina N, Boçari G, Iljazi A, et al. Maximum time of the effect of antileukotriene - zileuton in treatment of patients with bronchial asthma. Acta Inform Med. 2016;24:16–19.
   PubMedGoogle Scholar
• Kahnt AS, Rorsch F, Diehl O, et al. Cysteinyl leukotriene-receptor-1 antagonists interfere with PGE2 synthesis by inhibiting mPGES-1 activity. Biochem Pharmacol. 2013;86:286–296.
   PubMed Web of Science ®Google Scholar
• Theron AJ, Steel HC, Tintinger GR, et al. Cysteinyl leukotriene receptor-1 antagonists as modulators of innate immune cell function. J Immunol Res. 2014;2014:608930.
   PubMed Web of Science ®Google Scholar
• Bozek A, Warkocka-Szoltysek B, Filipowska-Gronska A, et al. Montelukast as an add-on therapy to inhaled corticosteroids in the treatment of severe asthma in elderly patients. J Asthma. 2012;49:530–534.
   PubMed Web of Science ®Google Scholar
• Lazarinis N, Bood J, Gomez C, et al. Leukotriene E4 induces airflow obstruction and mast cell activation through the cysteinyl leukotriene type 1 receptor. J Allergy Clin Immunol. 2018;142:1080–1089.
   PubMed Web of Science ®Google Scholar
• Price D, Popov TA, Bjermer L, et al. Effect of montelukast for treatment of asthma in cigarette smokers. J Allergy Clin Immunol. 2013;131:763–771.
   PubMed Web of Science ®Google Scholar
• Allayee H, Hartiala J, Lee W, et al. The effect of montelukast and low-dose theophylline on cardiovascular disease risk factors in asthmatics. Chest. 2007;132:868–874.
   PubMed Web of Science ®Google Scholar
• Ingelsson E, Yin L, Back M. Nationwide cohort study of the leukotriene receptor antagonist montelukast and incident or recurrent cardiovascular disease. J Allergy Clin Immunol. 2012;129:702–7.e2.
   PubMed Web of Science ®Google Scholar
• Trinh HKT, Pham DL, Choi Y, et al. Epithelial folliculin enhances airway inflammation in aspirin-exacerbated respiratory disease. Clin Exp Allergy. 2018;48:1464–1473.
   PubMed Web of Science ®Google Scholar
• Debelleix S, Siao-Him Fa V. Montelukast reverses airway remodeling in actively sensitized young mice. Pediatr Pulmonol. 2018;53:701–709.
   PubMed Web of Science ®Google Scholar
• Tenero L, Piazza M, Sandri M, et al. Effect of montelukast on markers of airway remodeling in children with asthma. Allergy Asthma Proc. 2016;37:77–83.
   PubMed Web of Science ®Google Scholar
• Gao J, Cai F, Wang B. Montelukast improves air trapping, not airway remodeling, in moderate-to-severe patients with asthma: a pilot study. Eur Respir J. 2013;126:2229–2234.
   Web of Science ®Google Scholar
• Hoshino M, Ohtawa J, Akitsu K, et al. Effect of the addition of montelukast on airway inflammation and remodeling in symptomatic asthma. Eur Respir J. 2017;50:PA4680.
   Web of Science ®Google Scholar
• Lynch KR, O’Neill GP, Liu Q, et al. Characterization of the human cysteinyl leukotriene CysLT1 receptor. Nature. 1999;399:789–793.
   PubMed Web of Science ®Google Scholar
• Christian Virchow J Jr, Prasse A, Naya I, et al. Zafirlukast improves asthma control in patients receiving high-dose inhaled corticosteroids. Am J Respir Crit Care Med. 2000;162:578–585.
   PubMed Web of Science ®Google Scholar
• Göbel T, Diehl O, Heering J, et al. Zafirlukast is a dual modulator of human soluble epoxide hydrolase and peroxisome proliferator-activated receptor γ. Front Pharmacol. 2019;10:263.
   Web of Science ®Google Scholar
• Lei C, Wu S, Wen C, et al. Zafirlukast attenuates advanced glycation end-products (AGEs)-induced degradation of articular extracellular matrix (ECM). Int Immunopharmacol. 2019;68:68–73.
   PubMed Web of Science ®Google Scholar
• Morita Y, Campos Alberto E, Suzuki S, et al. Pranlukast reduces asthma exacerbations during autumn especially in 1- to 5-year-old boys. Asia Pac Allergy. 2017;7:10–18.
   PubMed Web of Science ®Google Scholar
• Keam SJ, Lyseng-Williamson KA, Goa KL. Pranlukast: a review of its use in the management of asthma. Drugs. 2003;63:991–1019.
   PubMed Web of Science ®Google Scholar
• Hur J, Kang JY, Rhee CK, et al. The leukotriene receptor antagonist pranlukast attenuates airway remodeling by suppressing TGF-beta signaling. Pulm Pharmacol Ther. 2018;48:5–14.
   PubMed Web of Science ®Google Scholar
• Kim S, Lee JM. A case of pranlukast-induced anaphylactic shock. Allergy Asthma Immunol Res. 2016;8:276–278.
   PubMed Web of Science ®Google Scholar
• Kim SW, Kim H, Ryu YJ, et al. Efficacy and safety of modified pranlukast (Prakanon(®)) compared with pranlukast (Onon(®)): a randomized, open-label, crossover study. Open Respir Med. 2016;10:36–45.
   PubMedGoogle Scholar
• Bruno F, Spaziano G, Liparulo A, et al. Recent advances in the search for novel 5-lipoxygenase inhibitors for the treatment of asthma. Eur J Med Chem. 2018;153:65–72.
   PubMed Web of Science ®Google Scholar
• Zaman K, Hanigan MH, Smith A, et al. Endogenous S-nitrosoglutathione modifies 5-lipoxygenase expression in airway epithelial cells. Am J Respir Cell Mol Biol. 2006;34:387–393.
   PubMed Web of Science ®Google Scholar
• Trinh HKT, Suh DH, Nguyen TVT, et al. Characterization of cysteinyl leukotriene-related receptors and their interactions in a mouse model of asthma. Prostaglandins Leukot Essent Fatty Acids. 2019;141:17–23.
   PubMed Web of Science ®Google Scholar
• Sekioka T, Kadode M, Osakada N, et al. A new CysLT1 and CysLT2 receptors-mediated anaphylaxis guinea pig model. Prostaglandins Leukot Essent Fatty Acids. 2017;119:18–24.
   PubMed Web of Science ®Google Scholar
• Sekioka T, Kadode M, Fujii M, et al. Expression of CysLT2 receptors in asthma lung, and their possible role in bronchoconstriction. Allergol Int. 2015;64:351–358.
   PubMed Web of Science ®Google Scholar
• Gauvreau G, Boulet LP, FitzGerald J, et al. A dual Cys LT 1/2 antagonist attenuates allergen‐induced airway responses in subjects with mild allergic asthma. Allergy. 2016;71:1721–1727.
   PubMed Web of Science ®Google Scholar
• Gelfand EW. Importance of the leukotriene B4-BLT1 and LTB4-BLT2 pathways in asthma. Semin Immunol. 2017;33:44–51.
   PubMed Web of Science ®Google Scholar
• Pal K, Feng X, Steinke JW, et al. Leukotriene A4 hydrolase activation and leukotriene B4 production by eosinophils in severe asthma. Am J Respir Cell Mol Biol. 2018.
   Web of Science ®Google Scholar
• Evans DJ, Barnes PJ, Spaethe SM, et al. Effect of a leukotriene B4 receptor antagonist, LY293111, on allergen induced responses in asthma. Thorax. 1996;51:1178–1184.
   PubMed Web of Science ®Google Scholar
• Matsuse H, Kondo Y, Saeki S, et al. Naturally occurring parainfluenza virus 3 infection in adults induces mild exacerbation of asthma associated with increased sputum concentrations of cysteinyl leukotrienes. Int Arch Allergy Immunol. 2005;138:267–272.
   PubMed Web of Science ®Google Scholar
• Liu T, Laidlaw TM, Katz HR, et al. Prostaglandin E2 deficiency causes a phenotype of aspirin sensitivity that depends on platelets and cysteinyl leukotrienes. Proc Natl Acad Sci U S A. 2013;110:16987–16992.
   PubMed Web of Science ®Google Scholar
• Samuelsson B, Dahlen SE, Lindgren JA, et al. Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. Science. 1987;237:1171–1176.
   PubMed Web of Science ®Google Scholar
• Sala A, Voelkel N, Maxlouf J, et al. Leukotriene E4 elimination and metabolism in normal human subjects. J Biol Chem. 1990;265:21771–21778.
   PubMed Web of Science ®Google Scholar
• Cheung DS, Sigua JA, Simpson PM. Cysteinyl leukotriene receptor 1 expression identifies a subset of neutrophils during the antiviral response that contributes to postviral atopic aiway disease. J Allergy Clin Immunol. 2018;142:1206–17.e5.
   PubMed Web of Science ®Google Scholar
• Paruchuri S, Tashimo H, Feng C. Leukotriene E4-induced pulmonary inflamation is mediated by the P2Y12 receptor. J Exp Med. 2009;206:2543–2555.
   PubMed Web of Science ®Google Scholar
• Kanaoka Y, Maekawa A, Austen KF. Identification of GPR99 protein as a potential third cysteinyl leukotriene receptor with a preference for leukotriene E4 ligand. J Biol Chem. 2013;288:10967–10972.
   PubMed Web of Science ®Google Scholar
• Bankova LG, Lai J, Yoshimoto E. Leukotriene E4 elicits respiratory epithelial cell mucin release through the G-protein-coupled receptor, GPR99. Proc Natl Acad Sci U S A. 2016;113:6242–6247.
   PubMed Web of Science ®Google Scholar
• Shirasaki H, Kanaizumi E, Seki N, et al. Leukotriene E4 induces MUC5AC release from human airway epithelial NCI-H292 cells. Allergol Int. 2015;64:169–174.
   PubMed Web of Science ®Google Scholar
• Sub DH, Trinh HKT, Liu JN, et al. P2Y12 antagonist attenuates eosinophilic inflammation and airway hyperresponsiveness in a mouse model of asthma. J Cell Mol Med. 2016;20:333–341.
   PubMed Web of Science ®Google Scholar
• Dorsam RT, Kunapuli SP. Central role of the P2Y12 receptor in platelet activation. J Clin Invest. 2004;113:340–345.
   PubMed Web of Science ®Google Scholar
• Diehl J, Gries B, Pfeil U, et al. Expression and localization of GPR91 and GPR99 in murine organs. Cell Tissue Res. 2016;364:245–262.
   PubMed Web of Science ®Google Scholar
• Salimi M, Stoger L, Liu W, et al. Cysteinyl leukotriene E4 activates human group 2 innate lymphoid cells and enhances the effect of prostaglandin D2 and epithelial cytokines. J Allergy Clin Immunol. 2017;140:1090–100 e11.
   PubMed Web of Science ®Google Scholar
• Xue L, Barrow A, Fleming VM, et al. Leukotriene E4 activates human Th2 cells for exaggerated proinflammatory cytokine production in response to prostaglandin D2. J Immunol. 2012;188:694–702.
   PubMed Web of Science ®Google Scholar
• Foster HR, Fuerst E, Branchett W, et al. Leukotriene E4 is a full functional agonist for human cysteinyl leukotriene type 1 receptor-dependent gene expression. Sci Rep. 2016;6:20461.
   PubMed Web of Science ®Google Scholar
• Cummings HE, Liu T, Feng C. Cutting edge: leukotriene C4 activates mouse platelets in asthma exclusively through the type 2 cysteinyl leukotriene receptor. J Immunol. 2013;191:5807–5810.
   PubMed Web of Science ®Google Scholar
• Liu T, Barrett NA, Kanaoka Y, et al. Cysteinyl leukotriene receptor 2 drives lung immunopathology through a platelet and high mobility box 1-dependent mechanism. Mucosal Immunol. 2019;12:679–690.
   PubMed Web of Science ®Google Scholar
• Porreca E, Di Febbo C, Di Sciullo A, et al. Cysteinyl leukotriene D4 induced vascular smooth muscle cell proliferation: a possible role in myointimal hyperplasia. Thromb Haemost. 1996;75:099–104.
   Google Scholar
• Lee E, Robertson T, Smith J. Leukotriene receptor antagonists and synthesis inhibitors severe survival in eosinophils of asthmatic individuals. Am J Respir Crit Care Med. 2000;161:1881–1886.
   PubMed Web of Science ®Google Scholar
• Fehrenbach H, Wagner C, Wegmann M. Airway remodeling in asthma: what really matters. Cell Tissue Res. 2017;367:551–569.
   PubMed Web of Science ®Google Scholar
• Altraja S, Jaama J, Altraja A. Proteome change of human chronchial epithelial cells in response to pro-inflammatory mediator leukotriene E4 and pro-remodeling factor TGF-beta1. J Proteomics. 2010;73:1230–1240.
   PubMed Web of Science ®Google Scholar
• Ochkur SI, Protheroe CA, Li W, et al. Cys-leukotrienes promote fibrosis in a mouse model of eosinophil-mediated respiratory inflammation. Am J Respir Cell Mol Biol. 2013;49:1074–1084.
   PubMed Web of Science ®Google Scholar
• Papadaki G, Bakakos P, Kostikas K, et al. Vascular endothelial growth factor and cysteinyl leukotrienes in sputum supernatant of patients with asthma. Respir Med. 2013;107:1339–1345.
   PubMed Web of Science ®Google Scholar
• Espinosa K, Bossé Y, Stankova J, et al. CysLT1 receptor upregulation by TGF-β and IL-13 is associated with bronchial smooth muscle cell proliferation in response to LTD4. J Allergy Clin Immunol. 2003;111:1032–1040.
   PubMed Web of Science ®Google Scholar
• Bosse Y, Thompson C, McMahon S, et al. Leukotriene D4-induced, epithelial cell-derived transforming growth factor beta1 in human bronchial smooth muscle cell proliferation. Clin Exp Allergy. 2008;38:113–121.
   PubMed Web of Science ®Google Scholar
• Sugita K, Steer CA, Martinez-Gonzalez I, et al. Type 2 innate lymphoid cells disrupt bronchial epithelial barrier integrity by targeting tight junctions through IL-13 in asthmatic patients. J Allergy Clin Immunol. 2018;141:300–10.e11.
   PubMed Web of Science ®Google Scholar
• Calapai G, Casciaro M, Miroddi M, et al. Montelukast-induced adverse drug reactions: a review of case reports in the literature. Pharmacology. 2014;94:60–70.
   PubMed Web of Science ®Google Scholar
• Hon KL, Leung TF, Leung AK. Clinical effectiveness and safety of montelukast in asthma. What are the conclusions from clinical trials and meta-analyses? Drug Des Devel Ther. 2014;8:839–850.
   PubMed Web of Science ®Google Scholar
• Lee JH, Jung CG, Park HS. An update on the management of aspirin-exacerbated respiratory disease. Exp Rev Respir Med. 2018;12:137–143.
   PubMed Web of Science ®Google Scholar
• Kennedy JL, Stoner AN, Borish L. Aspirin-exacerbated respiratory disease: prevalence, diagnosis, treatment, and considerations for the future. Am J Rhinol Allergy. 2016;30:407–413.
   PubMed Web of Science ®Google Scholar
• Lee DKC, Haggart K, Robb FM, et al. Montelukast protects against nasal lysine-aspirin challenge in patients with aspirin-induced asthma. Eur Respir J. 2004;24:226–230.
   PubMed Web of Science ®Google Scholar
• Trinh HK, Ban GY, Lee JH, et al. Leukotriene receptor antagonists for the treatment of asthma in elderly patients. Drugs Aging. 2016;33:699–710.
   PubMed Web of Science ®Google Scholar
• Ye YM, Kim SH, Hur GY, et al. Addition of montelukast to low-dose inhaled corticosteroid leads to fewer exacerbations in older patients than medium-dose inhaled corticosteroid monotherapy. Allergy Asthma Immunol Res. 2015;7:440–448.
   PubMed Web of Science ®Google Scholar
• Miller A, Palecki A. Restrictive impairment in patients with asthma. Respir Med. 2007;101:272–276.
   PubMed Web of Science ®Google Scholar
• Saliman JA, Benditt JO, Flum DR, et al. Pulmonary function in the morbidly obese. Surg Obes Relat Dis. 2008;4:632–639.
   PubMed Web of Science ®Google Scholar
• Giouleka P, Papatheodorou G, Lyberopoulos P, et al. Body mass index is associated with leukotriene inflammation in asthmatics. Eur J Clin Invest. 2011;41:30–38.
   PubMed Web of Science ®Google Scholar
• Peters-Golden M, Swern A, Bird SS, et al. Influence of body mass index on the response to asthma controller agents. Eur Respir J. 2006;27:495–503.
   PubMed Web of Science ®Google Scholar
• Shimoda T, Obase Y, Kishikawa R, et al. Influence of cigarette smoking on airway inflammation and inhaled corticosteroid treatment in patients with asthma. Allergy Asthma Proc. 2016;37:50–58.
   PubMed Web of Science ®Google Scholar
• Schatz M, Zeiger RS, Vollmer WM, et al. Determinants of future long-term asthma control. J Allergy Clin Immunol. 2006;118:1048–1053.
   PubMed Web of Science ®Google Scholar
• Lazarus SC, Chinchilli VM, Rollings NJ, et al. Smoking affects response to inhaled corticosteroids or leukotriene receptor antagonists in asthma. Am J Respir Crit Care Med. 2007;175:783–790.
   PubMed Web of Science ®Google Scholar
• Leynaert B, Neukirch F, Demoly P, et al. Epidemiologic evidence for asthma and rhinitis comorbidity. J Allergy Clin Immunol. 2000;106:S201–S5.
   PubMed Web of Science ®Google Scholar
• Lisspers K, Janson C, Larsson K, et al. Comorbidity, disease burden and mortality across age groups in a Swedish primary care asthma population: an epidemiological register study (PACEHR). Respir Med. 2018;136:15–20.
   PubMed Web of Science ®Google Scholar
• Naydenova K, Velikova T, Dimitrov V. Interactions of allergic rhinitis and bronchial asthma at mucosal immunology level. AIMS Allergy Immunol. 2019;3:1–12.
   Google Scholar
• Khan DA. Allergic rhinitis and asthma: epidemiology and common pathophysiology. Allergy Asthma Proc. 2014;35:357–361.
   PubMed Web of Science ®Google Scholar
• Borderias L, Mincewicz G, Paggiaro PL, et al. Asthma control in patients with asthma and allergic rhinitis receiving add-on montelukast therapy for 12 months: a retrospective observational study. Curr Med Res Opin. 2007;23:721–730.
   PubMed Web of Science ®Google Scholar
• Philip G, Nayak AS, Berger WE, et al. The effect of montelukast on rhinitis symptoms in patients with asthma and seasonal allergic rhinitis. Curr Med Res Opin. 2004;20:1549–1558.
   PubMed Web of Science ®Google Scholar
• Kim JH, Lee SY, Kim HB, et al. Prolonged effect of montelukast in asthmatic children with exercise-induced bronchoconstriction. Pediatr Pulmonol. 2005;39:162–166.
   PubMed Web of Science ®Google Scholar
• Anderson SD, Kippelen P. Exercise-induced bronchoconstriction: pathogenesis. Curr Allergy Asthma Rep. 2005;5:116–122.
   PubMed Web of Science ®Google Scholar
• Peroni DG, Pescollderungg L, Sandri M, et al. Time-effect of montelukast on protection against exercise-induced bronchoconstriction. Respir Med. 2011;105:1790–1797.
   PubMed Web of Science ®Google Scholar
• Pearlman DS, Van Adelsberg J, Philip G, et al. Onset and duration of protection against excercise-induced bronchoconstriction by a single oral dose of montelukast. Ann Allergy Asthma Immunol. 2006;97:98–104.
   PubMed Web of Science ®Google Scholar
• Sigurs N. Epidemiologic and clinical evidence of a respiratory syncytial virus-reactive airway disease link. Am J Respir Crit Care Med. 2001;163:S2–6.
   PubMed Web of Science ®Google Scholar
• Oommen A, Grigg J. Urinary leukotriene E4 in preschool children with acute clinical viral wheeze. Eur Respir J. 2003;21:149–154.
   PubMed Web of Science ®Google Scholar
• Kellner JD, Ohlsson A, Gadomski AM, et al. Bronchodilators for bronchiolitis. Cochrane Database Syst Rev. 2000:CD001266. doi: 10.1002/14651858.CD001266.
   PubMedGoogle Scholar
• Bulow SM, Nir M, Levin E, et al. Prednisolone treatment of respiratory syncytial virus infection: a randomized controlled trial of 147 infants. Pediatrics. 1999;104:e77.
   PubMed Web of Science ®Google Scholar
• Bisgaard H, Study Group on M, Respiratory Syncytial V. A randomized trial of montelukast in respiratory syncytial virus postbronchiolitis. Am J Respir Crit Care Med. 2003;167:379–383.
   PubMed Web of Science ®Google Scholar
• Zeiger RS, Szefler SJ, Phillips BR, et al. Response profiles to fluticasone and montelukast in mild-to-moderate persistent childhood asthma. J Allergy Clin Immunol. 2006;117:45–52.
   PubMed Web of Science ®Google Scholar
• Rabinovitch N, Graber NJ, Chinchilli VM, et al. Urinary leukotriene E4/exhaled nitric oxide ratio and montelukast response in childhood asthma. J Allergy Clin Immunol. 2010;126:545–51.e14.
   PubMed Web of Science ®Google Scholar
• Kim C, Callaway Z, Park JS, et al. Montelukast reduces serum levels of eosinophil-derived neurotoxin in preschool asthma. Allergy Asthma Immunol Res. 2018;10:686.
   PubMed Web of Science ®Google Scholar
• Kim JH, Lee SY, Kim HB, et al. TBXA2R gene polymorphism and responsiveness to leukotriene receptor antagonist in children with asthma. Clin Exp Allergy. 2008;38:51–59.
   PubMed Web of Science ®Google Scholar
• Dahlin A, Litonjua A, Lima JJ, et al. Genome-wide association study identifies novel pharmacogenomic loci for therapeutic response to montelukast in asthma. PloS One. 2015;10:e0129385.
   PubMed Web of Science ®Google Scholar